Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Covidien, a global provider of healthcare products, reported that Mallinckrodt, a Covidien company, has received US Food and Drug Administration (FDA) approval for its abbreviated new drug application (ANDA) for its Fentanyl Transdermal System (FTS) patch.
Subscribe to our email newsletter
Covidien‘s FTS is a generic alternative to the branded Duragesic patch.
FTS, a Class II controlled substance, is an opioid analgesic indicated in opioid-tolerant patients for management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.
Covidien expects to launch FTS in the US in 25mcg/hr, 50mcg/hr, 75mcg/hr and 100mcg/hr strengths in the current quarter.
The plan is designed to minimize abuse and overdose, and includes patient and physician education material, a medication guide, and other tools to ensure patients who receive FTS understand the risks, appropriate use, storage, application and disposal of FTS.